Aslan Pharmaceuticals Ltd ADR
(ASLN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2020 | 03-2020 | 12-2019 | 09-2019 | 06-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 13,827 | 16,894 | 22,203 | N/A | N/A |
| Other current assets | 295 | 185 | 69 | 0 | 0 |
| TOTAL | $14,123 | $17,080 | $22,272 | $N/A | $N/A |
| Non-Current Assets | |||||
| PPE Net | 22 | 30 | 38 | N/A | N/A |
| Investments And Advances | 117 | 171 | 200 | 0 | 0 |
| Intangibles | 1 | 2 | 3 | 0 | 0 |
| Other Non-Current Assets | 703 | 769 | 836 | 0 | 0 |
| TOTAL | $843 | $972 | $1,078 | $N/A | $N/A |
| Total Assets | $14,966 | $18,052 | $23,350 | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,095 | 3,553 | 5,119 | 0 | 0 |
| TOTAL | $4,369 | $3,821 | $5,383 | $N/A | $N/A |
| Non-Current Liabilities | |||||
| Long Term Debt | 17,728 | 17,293 | 17,632 | N/A | N/A |
| Other Non-Current Liabilities | 997 | 810 | 938 | 0 | 0 |
| TOTAL | $18,596 | $18,103 | $18,570 | $N/A | $N/A |
| Total Liabilities | $22,965 | $21,924 | $23,953 | $N/A | $N/A |
| Shareholders' Equity | |||||
| Common Shares | 61,367 | 61,367 | 61,367 | N/A | N/A |
| Retained earnings | -186,491 | -182,532 | -179,485 | N/A | N/A |
| Other shareholders' equity | 629 | 797 | 1,019 | 0 | 0 |
| TOTAL | $-7,999 | $-3,872 | $-603 | $N/A | $N/A |
| Total Liabilities And Equity | $14,966 | $18,052 | $23,350 | $0 | $0 |